Analyst Price Targets — AAPG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 24, 2026 9:22 am | — | Deutsche Bank | $40.00 | $22.34 | TheFly | Ascentage Pharma initiated with a Buy at Deutsche Bank |
| December 4, 2025 11:37 am | Matthew Biegler | Oppenheimer | $45.00 | $30.33 | TheFly | Ascentage Pharma initiated with an Outperform at Oppenheimer |
| November 24, 2025 12:27 pm | Gregory Renza | Truist Financial | $51.00 | $30.64 | TheFly | Ascentage Pharma initiated with a Buy at Truist |
| November 5, 2025 8:40 am | Biren Amin | Piper Sandler | $48.00 | $33.25 | StreetInsider | Piper Sandler Starts Ascentage Pharma Group (AAPG) at Overweight |
Latest News for AAPG
The consensus price target hints at a 152.2% upside potential for Ascentage Pharma Group International - Unsponsored ADR (AAPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31st…
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced results from a Phase Ib study evaluating olverembatinib (HQP1351), the company's core…
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced that the Company presented its first dataset of alrizomadlin (APG-115), an MDM2-p53…
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AAPG.
U.S. House Trading
No House trades found for AAPG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.